Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-06-07
2010-08-03
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07767702
ABSTRACT:
The invention relates to combinations of A) oxazolidinones of formula (I) and B) other active ingredients, to a method for producing said combinations and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases.
REFERENCES:
patent: 2811555 (1957-10-01), Larive et al.
patent: 3279880 (1966-10-01), Straley et al.
patent: 4128654 (1978-12-01), Fugitt et al.
patent: 4250318 (1981-02-01), Dostert et al.
patent: 4327725 (1982-05-01), Cortese et al.
patent: 4500519 (1985-02-01), Lormeau et al.
patent: 4705779 (1987-11-01), Madi-Szabo et al.
patent: 4765989 (1988-08-01), Wong et al.
patent: 5002937 (1991-03-01), Bosies et al.
patent: 5254577 (1993-10-01), Carlson et al.
patent: 5349045 (1994-09-01), Jiang
patent: 5532255 (1996-07-01), Raddatz et al.
patent: 5561148 (1996-10-01), Gante et al.
patent: 5565571 (1996-10-01), Barbachyn et al.
patent: 5654285 (1997-08-01), Ingall et al.
patent: 5654428 (1997-08-01), Barbachyn et al.
patent: 5654435 (1997-08-01), Barbachyn et al.
patent: 5688792 (1997-11-01), Barbachyn et al.
patent: 5756732 (1998-05-01), Barbachyn et al.
patent: 5792765 (1998-08-01), Riedl et al.
patent: 5801246 (1998-09-01), Barbachyn et al.
patent: 5827857 (1998-10-01), Riedl et al.
patent: 5910504 (1999-06-01), Hutchinson
patent: 5922708 (1999-07-01), Riedl et al.
patent: 5929248 (1999-07-01), Barbachyn et al.
patent: 5972947 (1999-10-01), Tsaklakidis et al.
patent: 6069160 (2000-05-01), Stolle et al.
patent: 6159997 (2000-12-01), Tsujita et al.
patent: 6251869 (2001-06-01), Bohanon
patent: 6294201 (2001-09-01), Kettelhoit et al.
patent: 6805881 (2004-10-01), Kanikanti et al.
patent: 6818243 (2004-11-01), Nagashima et al.
patent: 7034017 (2006-04-01), Straub et al.
patent: 7078417 (2006-07-01), Rosentreter et al.
patent: 7109218 (2006-09-01), Rosentreter et al.
patent: 7129255 (2006-10-01), Rosentreter et al.
patent: 7157456 (2007-01-01), Straub et al.
patent: 7351823 (2008-04-01), Berwe et al.
patent: 2001/0029351 (2001-10-01), Falotico et al.
patent: 2003/0153610 (2003-08-01), Straub et al.
patent: 2003/0161882 (2003-08-01), Waterman
patent: 2004/0162427 (2004-08-01), Rosentreter et al.
patent: 2004/0242660 (2004-12-01), Straub et al.
patent: 2005/0064006 (2005-03-01), Perzborn et al.
patent: 2005/0182055 (2005-08-01), Berwe et al.
patent: 2005/0261502 (2005-11-01), Rosentreter et al.
patent: 2006/0154969 (2006-07-01), Rosentreter et al.
patent: 2006/0258724 (2006-11-01), Straub et al.
patent: 2007/0026065 (2007-02-01), Benke et al.
patent: 2007/0149522 (2007-06-01), Thomas
patent: 2008/0026057 (2008-01-01), Benke
patent: 2008/0090815 (2008-04-01), Straub et al.
patent: 2008/0200674 (2008-08-01), Straub et al.
patent: 744002 (1999-07-01), None
patent: 2 437 587 (2002-08-01), None
patent: 2 451 258 (2003-01-01), None
patent: 2 464 290 (2003-05-01), None
patent: 2836305 (1979-03-01), None
patent: 196 04 223 (1997-08-01), None
patent: 19962924 (2001-07-01), None
patent: 10129725 (2003-01-01), None
patent: 10355461 (2005-06-01), None
patent: 0 127 902 (1984-12-01), None
patent: 0 316 594 (1989-05-01), None
patent: 0 352 781 (1990-01-01), None
patent: 0350002 (1990-01-01), None
patent: 0 623 615 (1994-11-01), None
patent: 0645376 (1995-03-01), None
patent: 0 738 726 (1996-10-01), None
patent: 0 785 200 (1997-07-01), None
patent: 0930076 (1999-07-01), None
patent: 0950386 (1999-10-01), None
patent: 10105989 (2001-02-01), None
patent: 2140687 (1984-12-01), None
patent: WO-93/09103 (1993-05-01), None
patent: WO-93/23384 (1993-11-01), None
patent: WO-97/03072 (1997-01-01), None
patent: WO-97/09328 (1997-03-01), None
patent: WO-97/10223 (1997-03-01), None
patent: WO-9723212 (1997-07-01), None
patent: WO-98/01446 (1998-01-01), None
patent: WO-9811896 (1998-03-01), None
patent: WO-98/54161 (1998-12-01), None
patent: WO-99/02525 (1999-01-01), None
patent: WO-99/03846 (1999-01-01), None
patent: WO-99/06371 (1999-02-01), None
patent: WO-99/21535 (1999-05-01), None
patent: WO-99/24428 (1999-05-01), None
patent: 9931092 (1999-06-01), None
patent: WO-99/29688 (1999-06-01), None
patent: WO-99/31092 (1999-06-01), None
patent: WO-99/37304 (1999-07-01), None
patent: WO-99/37630 (1999-07-01), None
patent: WO-99/37641 (1999-07-01), None
patent: WO-99/40094 (1999-08-01), None
patent: WO-99/59616 (1999-11-01), None
patent: WO-00/16748 (2000-03-01), None
patent: WO- 01/42242 (2001-06-01), None
patent: WO-01/44212 (2001-06-01), None
patent: WO-01/46185 (2001-06-01), None
patent: 0147919 (2001-07-01), None
patent: WO-01/47949 (2001-07-01), None
patent: WO-02/064575 (2002-08-01), None
patent: WO-03/000256 (2003-01-01), None
patent: WO-03/035133 (2003-05-01), None
patent: WO-03/035133 (2003-05-01), None
patent: WO-2004/060887 (2004-07-01), None
patent: WO-2005/060940 (2005-05-01), None
patent: WO-2005/068456 (2005-07-01), None
patent: WO-2006/072367 (2006-07-01), None
patent: WO-2006/079474 (2006-08-01), None
patent: WO-2007/036306 (2007-04-01), None
patent: WO-2007/039122 (2007-04-01), None
patent: WO-2007/039132 (2007-04-01), None
patent: WO-2007/042146 (2007-04-01), None
patent: WO-2008/012002 (2008-01-01), None
patent: WO-2008/052671 (2008-02-01), None
Bono, F., et al, “Human Umbilical Vein Endothelial Cells Express High Affinity Receptors for Factor Xa”, Journal of Cellular Physiology, 1997, vol. 172, pp. 36-43.
Cocks, T. M., et al., “Protease-Activated Receptors: Sentries for Inflammation”, Tips, 2000, vol. 21, pp. 103-108.
Ross, R., “Atherosclerosis- An Inflammatory Disease”, New England J. of Medicine, 1999, vol. 340, No. 2, pp. 115-126.
Nakata, M., et al., “DX9065a an Xa Inhibitor, Inhibits Prothrombin-Induced A549 Lung Adenocarcinoma Cell Proliferation”, Cancer Letters, 1998, vol. 122, pp. 127-133.
Kaiser, B., et al., “A Synthetic Inhibitor of Factor Xa, DX-9065a, Reduces Proliferation of Vascular Smooth Muscle Cells in Vivo in Rats”, Thrombosis Research, 2000, vol. 98, pp. 175-185.
Altieri, D. C., et al., “Identification of Effector Cell Protease Receptor-1”, The Journal of Immunology, 1990, vol. 145, No. 1, pp. 246-253.
Coughlin, S. R., “Thrombin Signalling and Protease-Activated Receptors”, Nature, 2000, vol. 407, pp. 258-264.
Ornstein, D. L., et al., “Cancer, Thrombosis, and Anticoagulants”, Current Opinion in Pulmonary Medicine, 2000, vol. 6, pp. 301-308.
Dabbagh, K., et al., “Thrombin Stimulates Smooth Muscle Cell Procollagen Synthesis and mRNA Levels via a PAR-1 Mediated Mechanism”, Thrombasis and Haemostasis, vol. 79, No. 2 1997, pp. 405-409.
Herault, J-P., et al., “Activation of Human Vascular Endothelial Cells by Factor Xa: Effect of Specific Inhibitors”, Biochemical Pharmacology, 1999, vol. 57, pp. 603-610.
Leveugle, B., et al., “Heparin Oligosaccharides that Pass the Blood- Brain Barrier Inhibit β-Amyloid Precursor Protein Secretion and Heparin Binding to β-Amyloid Peptide”, Journal of Neurochemistry, 1998, vol. 70, No. 2, pp. 736-744.
Molino, M., et al., “Differential Expression of Functional Protease-Activated Receptor-2 (PAR-2) in Human Vascular Smooth Muscle Cells”, Arteriosclerosis, Thrombasis, and Vascular Biology, vol. 18, No. 5, 1998, pp. 825-832.
Plescia, J., et al., “Activation of MAC-1 (CD11b/CD18)-Bound Factor X by Release Cathepsin G Defines an Alternative Pathway of Leucocyte Initiation of Coagulation”, Biochem. J., 1996, vol. 319, pp. 873-879.
Howells, G. L., et al., “Proteinase-Activated Receptor-2: Expression by Human Neutrophils”, Journal of Cell Science, 1997, vol. 110, pp. 881-887.
Herbert, J.-M., et al., “Effector Protease Receptor 1 Mediates the Mitogenic Activity of Factor Xa for Vascular Smooth Muscle Cells in Vitro and In Vivo”, J. Clin. Invest., 1998, vol. 101, No. 5, pp. 993-1000.
Donnelly, K. M., et al., “Ancylostoma caninumAnticoagulant Peptide Blocks Metastasis In Vivo and Inhibits Factor Xa Binding to Melanoma Cells In Vitro”, Thromb Haemost, 1998, vol. 79,
Lampe Thomas
Pernerstorfer Josef
Perzborn Elisabeth
Pohlmann Jens
Röhrig Susanne
Bayer Schering Pharma Aktiengesellschaft
Connolly Bove & Lodge & Hutz LLP
Kwon Brian-Yong S
LandOfFree
Substituted oxazolidinones for combinational therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted oxazolidinones for combinational therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted oxazolidinones for combinational therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4150763